Drug profile

The FDA adverse-event record for Florfenicol + Mometasone Furoate + Terbinafine Hcl

19 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Florfenicol + Mometasone Furoate + Terbinafine Hcl. See the species affected, top reactions, and outcomes below.

19
adverse-event reports
0.0%
death-coded share
Dog
most-reported species
5
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
19
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

FlorfenicolMometasone FuroateTerbinafine Hcl

Administration Routes

UnknownAuricular (Otic)Topical

Species Affected

Dog 16
Cat 3

Most Affected Breeds

Retriever - Golden 3
Maltese 2
Retriever - Labrador 2
Domestic Shorthair 1
Ragdoll 1
Chihuahua 1
Cat (other) 1
Pekingese 1
Pug 1
Poodle - Standard 1

Most Reported Reactions

Vomiting 5
Vestibular disorder NOS 4
Ataxia 4
Lack of efficacy - NOS 4
Lack of efficacy (bacteria) - NOS 4
Otorrhoea 4
Unable to stand 3
Abnormal pupil light reflex 3
Other abnormal test result NOS 3
Abnormal cytology 3
Decreased appetite 3
Behavioural disorder NOS 2

Outcome Breakdown

Outcome Unknown
7 (36.8%)
Recovered/Normal
6 (31.6%)
Ongoing
6 (31.6%)

Florfenicol + Mometasone Furoate + Terbinafine Hcl Adverse Event Insights

19 reports name Florfenicol + Mometasone Furoate + Terbinafine Hcl; 0 recorded a death outcome (0.0% of reported events, not a population-level mortality rate). Active ingredients: Florfenicol, Mometasone Furoate, Terbinafine Hcl. Administration routes: Unknown, Auricular (Otic), Topical.

By species: Dog (16 reports), Cat (3 reports). By breed: Retriever - Golden (3), Maltese (2), Retriever - Labrador (2).

Leading clinical signs: Vomiting (5), Vestibular disorder NOS (4), Ataxia (4), Lack of efficacy - NOS (4). Outcome, 19 coded reports: Outcome Unknown leads at 36.8%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.